Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$0.51 - $2.45
Next Earnings Date
May 12 2025
Next Earnings Date
May 12 2025
Last Price
Market Cap | $49.72M |
EV | $23.75M |
Shares Outstanding | 44.09M |
Beta | 0.74 |
Analyst Rating | BUY |
Analyst Target Price | $7.25 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | - |
EPS | 24.40% |
Operating Cash Flow | 20.30% |
Free Cash Flow | 32.30% |
Revenue | - |
EPS | 33.20% |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | - |
ROCE 2024 | -98.63% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Quince Therapeutics, Inc.
QNCX
Sector
Healthcare
Industry
Biotechnology
CEO
Thye, Dirk
Employees
36
Website
www.quincetx.comIPO Date
2019-05-09
Headquarters
611 Gateway Boulevard, Suite 273, South San Francisco, California, 94080, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved